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Astrocytes infected with Chlamydia
pneumoniae demonstrate altered expression
and activity of secretases involved
in the generation of β‑amyloid found
in Alzheimer disease
Zein Al‑Atrache, Danielle B. Lopez, Susan T. Hingley and Denah M. Appelt*

Abstract
Background: Epidemiologic studies strongly suggest that the pathophysiology of late-onset Alzheimer disease (AD)
versus early-onset AD has environmental rather than genetic causes, thus revealing potentially novel therapeutic
targets to limit disease progression. Several studies supporting the “pathogen hypothesis” of AD demonstrate a strong
association between pathogens and the production of β-amyloid, the pathologic hallmark of AD. Although the mech‑
anism of pathogen-induced neurodegeneration of AD remains unclear, astrocytes, a key player of the CNS innate
immune response and producer/metabolizer of β-amyloid, have been implicated. We hypothesized that Chlamydia
pneumoniae infection of human astrocytes alters the expression of the amyloid precursor protein (APP)-processing
secretases, ADAM10, BACE1, and PSEN1, to promote β-amyloid formation. Utilizing immunofluorescent microscopy,
molecular, and biochemical approaches, these studies explore the role of an intracellular respiratory pathogen,
Chlamydia pneumoniae, as an environmental trigger for AD pathology. Human astrocytoma cells in vitro were infected
with Chlamydia pneumoniae over the course of 6–72 h. The gene and protein expression, as well as the enzymatic
activity of non-amyloidogenic (ADAM10), and pro-amyloidogenic (BACE1 and PSEN1) secretases were qualitatively
and quantitatively assessed. In addition, the formation of toxic amyloid products as an outcome of pro-amyloidogenic
APP processing was evaluated through various modalities.
Results: Chlamydia pneumoniae infection of human astrocytoma cells promoted the transcriptional upregulation of
numerous genes implicated in host neuroinflammation, lipid homeostasis, microtubule function, and APP processing.
Relative to that of uninfected astrocytes, BACE1 and PSEN1 protein levels were enhanced by nearly twofold at 48–72 h
post-Chlamydia pneumoniae infection. The processing of APP in Chlamydia pneumoniae-infected astrocytes favors the
pro-amyloidogenic pathway, as demonstrated by an increase in enzymatic activity of BACE1, while that of ADAM10
was decreased. Fluorescence intensity of β-amyloid and ELISA-quantified levels of soluble-APP by products revealed
temporally similar increases, confirming a BACE1/PSEN1-mediated processing of APP.
Conclusions: Our findings suggest that Chlamydia pneumoniae infection of human astrocytes promotes the proamyloidogenic pathway of APP processing through the upregulation of expression and activity of β-secretase,
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upregulated expression of γ-secretase, and decreased activity of α-secretase. These effects of astrocyte infection
provide evidence for a direct link between Chlamydia pneumoniae and AD pathology.
Keywords: Alzheimer disease, Neuroinflammation, Neurodegeneration, Amyloid, Astrocytes, Secretase, BACE1,
Chlamydia pneumoniae, Pathogens

Background
Alzheimer Disease (AD) is a chronic, progressive neurodegenerative illness regarded as the most common
cause of dementia, which afflicts 46.8 million people
worldwide—a number predicted to quadruple by the
year 2050 [1]. AD also ranks among the top 10 causes of
death in the US that can be neither prevented nor cured.
Several investigations have aimed at deciphering etiologies that suggest the multiple causes or triggers of AD
pathology [2, 3]. AD is diagnosed as one of two classifications: early-onset or familial AD, abbreviated EOAD or
FAD, or late-onset or sporadic AD, abbreviated LOAD
or SAD. Familial AD manifests symptoms at < 65 years of
age. These cases are predominantly genetic and account
for only 5% of all cases of AD. The majority of AD
patients that present with symptoms at > 65 years of age
are grouped into the category of late-onset AD. Numerous genome-wide association studies have identified that
certain risk-associated alleles are expressed differently in
patients suffering from EOAD/FAD versus LOAD/SAD
[4, 5]. However, the etiology of SAD pathology, unlike
that of FAD, is considered multifactorial rather than
strictly genetic.
In 1992, Hardy and Higgins [6] first introduced the
amyloid cascade hypothesis to explain the etiology of
AD, which proposes that beta-amyloid (Aβ) results from
the enzymatic processing of amyloid precursor protein
(APP). The amyloid cascade hypothesis claims that the
neurotoxicity triggered by Aβ initiates related pathologic processes such as formation of extracellular senile
plaques, which is one of the characteristic hallmarks of
AD. Senile plaques are composed of oligomerized Aβ and
are the pathologic findings in FAD and SAD brains. In its
monomeric form, Aβ is a 39–42 amino acid peptide fragment derived from the sequential cleavage of APP, a large,
type I transmembrane protein. APP processing can occur
in two pathways, the non-amyloidogenic pathway or the
pro-amyloidogenic pathway. The initial APP-processing
event is catalyzed predominantly by the α-secretase, a
disintegrin and metalloproteinase-10 (ADAM10) in the
non-amyloidogenic pathway [7], and the β-secretase,
β-site APP cleaving enzyme 1 (BACE1), in the pro-amyloidogenic pathway [8, 9]. A second cleavage event is
performed by a γ-secretase, a complex containing 4 subunits: presenilin 1 or 2 (PSEN1 or PSEN2), as the catalytic
subunit, nicastrin (NCSTN), anterior pharynx defensive

phenotype 1 (APH1) and presenilin enhancer-2 (PEN2)
[10, 11]. Cleavage of APP by ADAM10 or BACE1 releases
the soluble amino terminal products, soluble APP-α
(sAPPα) or soluble APP-β (sAPPβ), respectively, and carboxy terminal fragments, C83 and C99, respectively. In
the non-amyloidogenic pathway, C83 is further cleaved
by PSEN into the APP intracellular domain (AICD) and
a p3 peptide, a non-toxic form of amyloid. Whereas in
the amyloidogenic pathway, PSEN cleaves C99 into AICD
and Aβ fragments, of which the 42 amino acid fragment
(Aβ1-42) is considered the most neurotoxic [12]. Due to
its hydrophobic characteristics, Aβ1-42 acts as a nidus for
seeding additional Aβ peptide fragments, thereby facilitating large, extracellular aggregations of Aβ [13, 14].
In the context of SAD pathogenesis, the well-established mutations of APP and PSEN that promote
enhanced pro-amyloidogenic processing of APP in FAD
are not implicated; rather, exogenous stimuli, such as
environmental toxins or infectious pathogens that may
alter their overall expression are implicated [15]. These
exogenous stimuli trigger the activation of both neuronal
and non-neuronal cells with subsequent release of proinflammatory cytokines and activation of intracellular
signaling pathways [16, 17]. As a result of these types of
stressors, activated glial and neuronal cell models have
demonstrated increased transcriptional expression, and/
or altered activity of ADAM10, BACE1, and PSEN1
[18–20]. The etiology of neurodegeneration in SAD
may therefore result from, at least in part, the effects of
exogenous stimuli on the expression of APP-processing
secretases.
One such stimulus that has garnered significant support as a potential trigger of SAD pathology is infection
of the CNS by various pathogens. Several pathogens
that have been implicated in SAD include cytomegalovirus, herpes simplex virus type 1, Borrelia burgdorferi,
and Chlamydia pneumoniae (Cpn) [21, 22]. The role of
Cpn in SAD pathology has been illustrated at both the
epidemiologic and cellular levels. This relationship was
first cited in the seminal study by Balin et al. [23] that
demonstrated that metabolically active Cpn was found
by immunohistochemical, electron microscopic, and
PCR techniques to be localized to areas of AD pathology in 17 of 19 post-mortem AD brains compared to 1
of 19 non-AD control brains. Another study validated the
presence of viable Cpn in 80% of AD brains (versus 11.1%
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of age-matched controls) via multiple methods including
in situ hybridization and PCR analysis of Cpn-specific
targets [24]. Additional evidence for a causal relationship between Cpn and AD was demonstrated through
intranasally inoculating the non-genetically manipulated
BALB/c mouse with Cpn isolates from AD brains [25].
In that study, Aβ deposits associated with Cpn infection were found in brain areas that are typically affected
in AD such as the hippocampus, the dentate gyrus and
the amygdala. These plaques were surrounded by reactive
astrocytes and, at times, encircled brain vasculature, suggesting the presence of cerebral amyloid angiopathy.
Epidemiologic assessments of Cpn and other infectious
burdens in control versus AD brains show a correlation
between infection and AD [21, 22, 24]. This evidence
supports the hypothesis that the chronic neuronal and
glial cell dysfunction visualized in the brains of SAD
patients may be derived from early-acquired CNS infection by Cpn and similar intracellular pathogens with the
potential to persist over time and reactivate from latency
or persistence.
An investigation into aberrant APP metabolism and
Aβ accumulation in the setting of inflammation needs
to include an analysis of the role of astrocytes, the most
abundant glial cells in the CNS. A common observation
among studies investigating Cpn in post-mortem AD
brains [23] and brains of Cpn-inoculated BALB/c mice
[25] was the colocalization of Cpn and GFAP-labeled
astrocytes, suggesting astrogliosis in response to Cpn
infection. It is interesting to note that glial activation in
AD patients is not uncommon, as revealed by PET imaging during the pre-symptomatic stages of AD, and is
shown to correlate with the initial signs of Aβ accumulation [26]. Animal models and in vitro studies indicate
that astrocytes respond to immune- and AD-associated
triggers, such as TNF-α, IFN-γ, IL-1β, bacterial lipopolysaccharide and Aβ by releasing cytokines and modifying
the expression and activity of APP processing enzymes,
which in turn exacerbate neuroinflammatory and neuropathological changes in the AD brain [19, 20, 27–30].
These findings support the contention that reactive
astrocytes contribute to the neurodegeneration and loss
of cognition observed in AD. Therefore, investigating
the effect of infection by Cpn on the processing of APP
by astrocytes is invaluable in modeling potential mechanisms by which Cpn may trigger sporadic AD pathology,
especially over time.
This study is aimed at investigating the effects of infection by Cpn on genes and the gene products involved in
the processing of APP to produce Aβ, which is a major
characteristic of AD pathology. By examining the effect
of Cpn infection on validated pathways of astrocytic APP
processing, this study provides evidence to support that
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AD pathology is recapitulated by infection with Cpn. This
investigation explores how the expression and activity of
APP-processing machinery, as defined by the amyloid
cascade hypothesis, is altered as a result of Cpn infection
of STTG1 human astrocytoma cells. The STTG1 human
astrocytoma cell line has been suggested to be a valuable in vitro model for AD and its experimental therapies. This is due to STTG1’s heterozygous expression of
the ApoE ε3/4 gene, its active participation in the proinflammatory cascade, and ability to both synthesize and
breakdown Aβ [31–34]. Therefore, this in vitro model of
Cpn infection of the CNS not only enhances our understanding of pathologic AD mechanisms, but also brings
to light new research avenues investigating “the pathogen
hypothesis” for early diagnosis and treatment of sporadic
AD.

Methods
Cell culture and infection with Chlamydia pneumoniae

The human astrocytoma cell line CCF-STTG1 (CRL1718) was obtained from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were grown
at 37 °C and 5% C
 O2 as a monolayer in culture medium
RPMI-1640 (ATCC, 10-2001) supplemented with 10%
(v/v) fetal bovine serum (FBS) in culture flasks (Corning Cell Culture Treated Flasks). Cells were trypsinized
(Thermofisher) and transferred to 12 or 6 well polystyrene plates (Corning® CellBIND®) in culture medium
for the western blot and RT-PCR experiments. For the
immunocytochemistry experiments, cells were grown
on 18.5 mm glass coverslips (neuvitro, GG-18-1.5-pre)
in sterile 12-well plates. For cell infection experiments,
50% of conditioned growth media was removed and Cpn
strain AR39 (ATCC, 52592) at MOI = 1 was added to
5 × 104 to 1 × 105 cells/well. To minimize variability Cpn
lot number was held constant throughout experiments
and each time point for a given experiment was inoculated on the same day. After centrifugation at 300×g
for 30 min at RT, fresh growth media was added and
cells were incubated for 6, 24, 48, and 72 h. Uninfected
cells used as a negative control were processed in parallel with Cpn-infected cells. This procedure describes the
preparation for one biological replicate. Each timepoint
was repeated to achieve samples in biological triplicate,
for which each was run in at least technical triplicate for
western blot analysis, ELISA, immunocytochemistry, and
molecular studies. Additional information of sample sizes
for each study is included in its respective figure legend.
Immunocytochemistry

Cells grown on sterile 18.5 mm glass coverslips were incubated with the following primary antibodies: anti-Aβ1-42
at 1:500 (Synaptic Systems, 218703); anti-ADAM 10 at
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1:100 (abcam ab39180), anti-BACE1 at 1:500 (abcam,
ab10716), anti-presenilin-1 at 1:500 (ProSci 4203). Secondary antibody was used at 1:500 (Alexa F
 luor® 594);
FITC-conjugated chlamydial antibodies (Fitzgerald,
61C75-A and 60C19) were used at 1:100 to visualize the
infection. BD Perm/Wash™ was used to as the antibody
diluent and cell wash buffer. Coverslips were mounted
on glass slides using FLUORO-GEL II with DAPI (EMS,
17985-50). Images were acquired using an Olympus
FV1000 laser scanning confocal microscope with a 60×,
1.4NA oil immersion objective lens and FluoView 1000
software. For cell counts, images were acquired at 40×
using the Nikon Eclipse 90i epi-fluorescence microscope.
Alzheimer disease RT‑PCR array

Cells were harvested and RNA was isolated in biological
triplicate from Cpn infected and uninfected astrocytes at
each timepoint post-infection. Purified RNA was reversetranscribed using R
 T2 First Strand Kit (Qiagen, 330401).
To ensure that the comparisons of gene expression were
valid for each timepoint post-infection, an equal amount
of RNA template from uninfected and Cpn-infected cells
within each timepoint was used for cDNA synthesis.
cDNA was used to profile 84 different genes included in
the Human Alzheimer Disease RT2 Profiler ™ PCR Array
(Qiagen, PAHS-057ZC). Web-based PCR array data analysis software provided by Qiagen was used to collectively
analyze raw Ct values for each AD-related gene included
in the assay [35]. Human β-actin was automatically chosen by the analysis software as the housekeeping gene
for standardization. Once each assay was normalized
to β-actin, ΔCt values for each gene of interest in Cpninfected cells were compared to that of uninfected cells
to obtain a fold change between gene of interest expression in uninfected cells and that of Cpn-infected cells for
each timepoint. Statistical significance in fold change values were determined by the Qiagen online analysis software, which uses a two-tailed student’s t test to compare
gene expression in infected and uninfected samples. Statistically significant changes in expression of AD-related
genes are listed in Additional File 1.
Western blot analysis

At the indicated timepoints post-infection, uninfected
and Cpn-infected cells were lysed using 1 × RIPA lysis
buffer (EMD Millipore, 20-188) supplemented with 1×
protease inhibitor (Halt ™ Protease Inhibitor 100×,
Thermo Scientific, 78430). Cell lysates were homogenized mechanically with mortar and pestle and through
ice-cold sonication before resolving on 4–20% precast polyacrylamide gels (Bio-Rad, Mini-PROTEAN®
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TGX™ gels, 456-1094) using 1× Tris/glycine/SDS
running buffer (Bio-Rad, 161-0732). Gels were transferred onto nitrocellulose membrane (iBlot® transfer
stack, Life Technologies, IB3010-02). Membranes were
then washed with wash buffer (Pierce ® Fast Western
Blot Kit, Thermo Scientific, 35050) and labeled (24 h
at 4 °C with gentle agitation) with primary antibodies
diluted in antibody diluent (Pierce ® Fast Western Blot
Kit, Thermo Scientific, 35050). The following primary
antibodies were used: anti-ADAM10 at 1:400 (Santa
Cruz Biotechnology, sc-48400), anti-BACE1 at 1:500
(abcam, ab108394), anti-presenilin-1 at 1:500 (abcam,
ab76083), anti-chlamydial antibody at 1:200 (Fitzgerald 10C27B), and to label the housekeeping protein
of interest, anti-β-actin at 1:500 (Santa Cruz Biotechnology, sc-8432). The following secondary antibodies
were used: goat anti-mouse and anti-rabbit conjugates
at 1:500 (Bio-Rad, 170-5046 and 170-5047, respectively). SuperSignal® West Pico Chemiluminescent
Substrate (Thermo Scientific, 34080) was then applied
to the membranes and visualized using Bio-Rad VersaDoc Imaging System 4000MP. Densitometry analysis was conducted using FIJI software [36]. ADAM10,
BACE1, and PSEN1 expression were assessed using the
same samples, ensuring that the expression of each of
these proteins could be accurately compared to each
other. The expression of each protein of interest was
quantified in 5–7 total samples. To determine statistical significance between protein levels derived from
Cpn infected and uninfected cells, student’s t-test was
conducted on the optical density values of each protein
of interest normalized to that of β-actin as a loading
control.
Quantitative analysis of Aβ1‑42 using immunofluorescence

Following immunolabeling with anti-Aβ1-42 as previously described, thirty 2 μm Z-stack images were
acquired across 3 separate coverslips (approximately
10 cells per coverslip) to ensure that representative
populations of cells were captured and that the entire
3-dimensional depth of labeled Aβ was included in the
analysis. Using FIJI software [36], each Z-stack image
was separated into its three individual channels; DAPI
and FITC were removed at this point and analysis was
performed on the TRITC channel. From each analyzed
image, a single 2D composite image was resolved to
represent the maximum fluorescence intensity of each
pixel of each 0.2 μm slice. Threshold fluorescence level
was defined to include all Aβ labeling within the area
of the cell. Mean fluorescence intensity of Aβ fluorescence exceeding the threshold fluorescence level was
obtained for each imaged cell and a student’s t-test was
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conducted to determine statistical significance of Aβ1-42
fluorescence intensity between infected and uninfected
cells for 24, 48 and 72 h timepoints.
Quantitative analysis of soluble APPα and APPβ using
Meso Scale Discovery (MSD) ELISA

At the indicated timepoints post-infection, conditioned media from Cpn-infected and uninfected cells
was removed and stored at − 80 °C. One milliliter of the
conditioned media was thawed and concentrated using
Eppendorf Vacufuge Plus at 45 °C. The MSD 96-well
MULTI-SPOT sAPPα/sAPPβ assay was performed as
directed by the manufacturer. Inter- and intra-assay %CV
are listed in Additional File 2. Concentration readings of
each individual sample (3 for each timepoint post-infection and infection status) of sAPPβ were divided by total
sAPP (sAPPα + sAPPβ) to obtain a ratio of sAPPβ to total
sAPP in the conditioned media of uninfected and Cpninfected treatment groups.
ADAM10 and BACE1 Activity Assay

AnaSpec Sensolyte 520 ADAM10 and BACE1 Activity Assay Kits (AS72226 and AS71144, respectively)
were used as a fluorimetric method for determining
ADAM10 and BACE1 activity in Cpn-infected and uninfected astrocytes. After 48 hpi, cells were counted, (data
not shown in results) harvested and placed into prechilled microcentrifuge tubes with pre-packed pestle for
homogenization. Cells were washed with ice-cold PBS,
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and pelleted at 4 °C and 800×g for 10 min (4 samples
for each treatment group). Mechanical and liquid nitrogen snap-freeze homogenization of fresh lysate allowed
for retrieval of lysate without compromising enzymatic
activity. Each enzyme assay was performed as directed
by the manufacturer. Each sample was assayed in technical duplicate. Completed assays were loaded in a black,
clear bottom plate and incubated at 37 °C for 1 h, then
analyzed at Ex/Em 490/520 using a Fluoroskan Ascent
FL microplate fluorometer. Background fluorescence of
assay buffer was subtracted from final fluorescence measurements and each final measurement was normalized
based on the protein concentration as determined by
BCA protein assay (Pierce, 23225).

Results
Chlamydia pneumoniae infects STTG1 human astrocytoma
cells in vitro and is maintained through 72 h post infection

As visualized via confocal microscopy, the respiratory
strain of Cpn, strain AR39, robustly infects STTG1 astrocytoma cells in vitro and persists 72 h post-infection
(hpi) (Fig. 1a). Percent infected cells, averaged across
approximately 2000–2500 cells per timepoint, is shown
in Fig. 1b. Percentages of infected cells were significantly
different between 6 hpi versus 48 hpi and 72 hpi, 24 hpi
versus 48 hpi and 72 hpi. This was determined through
conducting a one-way ANOVA, demonstrating p < 0.05,
and confirmed with Tukey HSD post hoc analysis. These

Fig. 1 Chlamydia pneumoniae infects human astrocytes in vitro. STTG1 human astrocytes infected with Cpn strain AR39 at an MOI of 1
demonstrated a diffuse punctate labeling of Cpn (green) from 6 to 72 hpi. Nuclei are labeled with DAPI (blue). Scale bar represents 20 μm (a).
Infected versus uninfected cell counts were averaged across approximately N = 2000–2500 cells per timepoint and in biological triplicate across two
independent infections. Numerical data is expressed as percent infected cells (b). Percentages of infected cells were significantly different between
6 hpi versus 48 hpi and 72 hpi, 24 hpi versus 48 hpi and 72 hpi. Comparisons between populations were determined through one-way ANOVA,
where significance was defined as p < 0.05, and confirmed using Tukey HSD post hoc analysis. Error bars represent standard deviation of the mean
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data indicate that Cpn infects human astrocytoma cells
within 6 hpi and appears to remain viable within these
cells for at least 72 h, although the numbers of infected
cells decrease after 24 hpi.
Chlamydia pneumoniae infection of human astrocytes
alters the transcript expression of AD‑related genes

The human Alzheimer disease array revealed that
Cpn infection at each timepoint post-infection altered
the expression of several genes directly and indirectly
involved with the development of AD pathology through
APP processing and tau-related mechanisms. The fold
changes in expression of the 84 AD-related genes in Cpninfected cells, compared to that of uninfected cells were
standardized to β-actin. At 6, 24, 48, and 72 hpi, significant changes in mRNA expression were observed in 40,
33, 35, and 17 different genes, respectively. The remaining
genes were not included in our analysis due to the lack
of a significant difference in their expression (p > 0.05).
The functional roles of these genes (Fig. 2a) in astrocytes
are aberrant in multiple pathways of AD, including lipid
metabolism (apolipoprotein E, APOE; lipoprotein lipase,
LPL; lipoprotein receptor-related protein 1, LRP1),
microtubule
organization
(microtubule-associated
protein 2, MAP2; microtubule-associated protein tau,
MAPT; glycogen synthase kinase 3β, GSK3B), and neuroinflammation (interleukin 1-α, IL1A) [29, 37–39]. Moreover, expression of genes associated with several of these
pathways have been shown to be altered upon infection
with Cpn [40–42]. An additional subset of genes included
in this analysis encode the secretases involved in APP
processing, as well as APP itself. The transcripts of APP,
ADAM10, BACE1, and subunits of the γ-secretase complex (PSEN1, PSEN2 APH1A and NCSTN) were significantly upregulated (p < 0.05) in at least one of the 4
investigated timepoints post-infection (Fig. 2b).
Cpn had its greatest effect on the transcriptional
expression of APP-processing secretases 6, 24, and
48 hpi. The altered gene expression observed as early as
6 hpi indicates that early Cpn entry into the astrocyte host
may act as a trigger for the expression of genes required
for the processing of APP. The increase in expression
of APP (33%), PSEN1 (39%), PSEN2 (17%) and APH1A
(20%) observed in infected cells compared to uninfected
cells was greatest at 6 hpi, while that of ADAM10 and
BACE1 was most elevated at 24 and 48 hpi (approximately 30–50% over that of uninfected cells). PSEN1,
PSEN2 and APH1A function in concert with nicastrin,
which demonstrated the greatest increase in expression
at 48 hpi (approximately 30% over that of uninfected
cells), to form the γ-secretase complex (Fig. 2b).
Our data indicate that the greatest increase in expression of secretase genes occurred within the first 48 hpi,
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though apparently neither the pro- nor the non-amyloidogenic pathway is favored, since expression of both
the α-secretase (ADAM10) and β-secretase (BACE1)
were similarly increased. These findings suggest that
Cpn infection may be enhancing the processing of APP
through transcriptional upregulation of secretase-associated genes.
Chlamydia pneumoniae infection of astrocytes alters
the expression of the APP processing secretases

To determine whether Cpn-induced transcriptional
changes in ADAM10, BACE1, and PSEN1 expression
were consistent at the protein level, these proteins were
visualized in Cpn-infected cells via confocal immunofluorescence. As ADAM10, BACE1, and PSEN1 proteins
mature, they are recycled between the plasma and endosomal membranes [12], however, the antibodies used to
visualize them in this study were chosen to be non-selective for intracellular and plasma membrane-localized
populations. For example, BACE1’s C-terminal domain
was targeted, which will detect BACE as it is recycled to
and from endosomes and the plasma membrane or as it
is shuttled through the late endosome/lysosome pathway.
Overall, the total fluorescence of each labeled protein
in Cpn-infected cells showed very subtle differences at
each timepoint post-infection compared to that of uninfected cells. ADAM10 labeling was not qualitatively different in Cpn-infected versus uninfected cells; BACE1
and PSEN1 labeling did show noticeable variations
post-Cpn infection (Fig. 3). In our studies, the pattern of
BACE1 labeling differed between uninfected and infected
astrocytes, potentially representing localization to cellular membranes in Cpn-infected cells, though the intensity of BACE1 labeling appeared unchanged. Labeling of
PSEN1, on the other hand, did appear increased in Cpninfected relative to uninfected astrocytes.
Chlamydia pneumoniae infection of astrocytes increases
the protein expression of secretases involved in APP
processing

To examine Cpn’s regulatory dynamics on the non-amyloidogenic processing pathway, total cell lysates from Cpn
infected and uninfected cells at 24, 48, and 72 hpi were
harvested for western blot analysis to semi-quantitatively
assess the expression of ADAM10 (α-secretase), BACE1
(β-secretase) and PSEN1 (a component of the γ-secretase
complex). Densitometry histograms of fold change of
ADAM10, BACE1 or PSEN1 protein levels in Cpninfected cells represent the average change in protein
levels across 5–7 replicates per time point, normalized
to that of β-actin within each sample and shown relative
to the amount of the respective protein present in uninfected cells for each timepoint (Fig. 4).
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The ADAM10 antibody used for western blots detected
an immature, proenzyme form of ADAM10 (~ 90 kDa),
the initiating enzyme for this pathway. Full length
ADAM10 requires posttranslational modifications to
be active, therefore the ADAM10 labeling presented in
these analyses detects inactive enzyme [12]. Compared
to that of uninfected samples, Cpn-infected astrocyte cell
lysates showed a statistically significant 1.4 fold increase
in ADAM10 protein levels (p < 0.05) at 24 hpi, but no
significant changes were measured at other timepoints,
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although the trend at 72 hpi indicated increased protein
levels in infected cells at this timepoint (Fig. 4).
The protein expression of BACE1 was assessed to
determine Cpn’s effect on the pro-amyloidogenic processing of APP. The BACE1 labeling observed at approximately 75 kDa corresponds to the mature form of the
protein. Mature BACE1 protein levels detected in Cpninfected versus uninfected cell lysates significantly
increased by 1.9 and 2.2 fold after 48 and 72 hpi, respectively, over that of uninfected cells (Fig. 4). These data

Fig. 2 Chlamydia pneumoniae infection of human astrocytes alters the transcript expression of AD-related genes. Gene transcripts from
Cpn-infected and uninfected cells analyzed at all four timepoints post-infection revealed significant fold changes in genes closely related to AD
pathology. The fold changes of fourteen genes implicated in known pathways of AD pathology are presented in a. Histograms of fold changes of
these AD-associated genes are presented in b. All expression data was normalized to β-actin and Cpn-infected and uninfected cDNA samples were
repeated in biological (N = 3) and technical triplicate for each timepoint. Asterisk indicates p < 0.05. ADAM10, A disintegrin and metalloproteinase
10; APH1A, anterior pharynx defective protein 1A; APOE, apolipoprotein E; APP, amyloid precursor protein; BACE1, βAPP-cleaving enzyme 1;
GSK3B, glucogen synthase kinase 3-β; IL1A, interleukin 1α; LPL, lipoprotein lipase; lipoprotein receptor-related protein 1, LRP1; MAP2, microtubule
associated protein 2; MAPT, microtubule associated protein tau; NCSTN, nicastrin; PSEN1, presenilin-1, PSEN2, presenilin-2
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Fig. 3 Chlamydia pneumoniae infection of astrocytes alters labeling of secretases. Astrocytes infected with Cpn from 6 to 72 hpi were double
labeled for Cpn (green) and secretases ADAM10, BACE1 or PSEN1 C-terminal fragment (red). 10–15 cells per biological replicate were imaged against
an equal number of uninfected control cells. Cells were visualized using laser scanning confocal microscopy, maintaining the voltage settings of
each color channel identical across biological replicates. DAPI was used to visualize the nucleus. Representative images are included this figure.
Scale bar represents 20 μm

suggest that Cpn infection results in a more extensive
increase in protein levels of intracellular BACE1 relative
to ADAM10, which may promote a pro-amyloidogenic
rather than a non-amyloidogenic processing pathway of
APP. Additionally, the increase in BACE1 protein expression observed with these studies does not seem transient;
as time of infection progresses, BACE1 protein levels
continued to increase throughout the 72 h of infection.
Active PSEN1 is localized to numerous subcellular
compartments of the cell [43]. The antibody used for
PSEN1 labeling via western blot analysis did not detect
intracellular levels of full length PSEN1, which appears
at 50 kDa, but rather a 20 kDa band, indicating proteolytically cleaved, and therefore active, carboxy terminal
fragment (CTF) of PSEN1. At all timepoints tested (24,
48, and 72 hpi), PSEN1 CTF protein levels detected in
Cpn-infected cell lysates were significantly increased
over those of uninfected controls (p < 0.05) (Fig. 4).
Corroborating the observations made via confocal

immunofluorescence, these western blot results provide
additional evidence for the role of Cpn in facilitating the
accumulation of potentially active PSEN1.
Fluorescence intensity of Aβ1‑42 is increased in Chlamydia
pneumoniae infected astrocytes

Approximately 30 Z-images of uninfected and Cpninfected cells were acquired for each timepoint and
resolved into a single, 2D representation of the maximum
Aβ1-42 fluorescence intensity of each 0.2 μm optical section (Fig. 5a). Aβ1-42 was localized within all cells, regardless of treatment group, indicating constitutively active
APP-processing. Mean Aβ1-42 fluorescence intensity in
Cpn-infected astrocytes, relative to that of uninfected
cells, did not differ significantly at 24 hpi; however, it was
elevated in infected cells at 48 and 72 hpi relative to uninfected cells from the same timepoint (Fig. 5b), indicating
an increase in pro-amyloidogenic processing of APP at
later times of infection.
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Fig. 4 Protein expression of ADAM10, BACE1 and PSEN1 in Chlamydia pneumoniae-infected and uninfected astrocytes. Whole cell lysate was
harvested from Cpn-infected and uninfected astrocytoma cells, resolved via SDS-PAGE gel electrophoresis, and labeled for secretase proteins. Fold
change represents densitometry analysis for protein levels of full-length ADAM10, BACE1 and PSEN1 C-terminal fragment in Cpn-infected cells
compared to that of uninfected cells at the same timepoint post infection. All densitometry values were normalized to that of β-actin for each
biological replicate (N = 5–7). Statistical analysis was conducted using student’s T-test of fold change within each timepoint (asterisk indicates
p < 0.05). Error bars represent standard error of the mean

Chlamydia pneumoniae infection alters the activity
of ADAM10 and BACE1 in initiating cleavage of APP

To study Cpn’s effect on ADAM10 and BACE1 activities in the initial cleavage of APP, MSD ELISA was used
to quantify the concentration of soluble APPα (sAPPα)
and soluble APPβ (sAPPβ) in the conditioned media of
uninfected and Cpn-infected cells. Corroborating the significantly increased intracellular Aβ1-42 at 48 and 72 hpi,
we observed a significant increase in the ratio of sAPPβ/
total sAPP, expressed as a percentage (Fig. 6), at 48 and
72 hpi in Cpn-infected cells when compared to that of
uninfected cells (p < 0.05). The levels of sAPPβ relative to
total sAPP released by uninfected cells did not vary significantly between time points, suggesting a regulated
balance of APP processing by ADAM10 and BACE1.
Chlamydia pneumoniae infection of astrocytes results
in increased activity of BACE1 and decreased activity
of ADAM10

The enzymatic activity of ADAM10 and BACE1 is contingent upon post-translational modifications that affect
each enzyme’s trafficking to the optimal subcellular compartments for APP cleavage [12, 44]. To determine if
Cpn-induced altered expression of ADAM10 and BACE1
at the protein level correlated to their altered enzymatic
activity, fluorimetric FRET-based enzyme assays were
conducted on whole cell lysate of uninfected and Cpninfected cells. Compared to that of uninfected cells, the
concentration of ADAM10-cleaved, fluorescent substrate

in Cpn-infected cell lysate at 48 hpi exhibited an overall
decreased trend in ADAM10 activity (Fig. 7). In contrast,
the concentration of BACE1-cleaved, fluorescent substrate generated by Cpn-infected cell lysate 48 hpi was
significantly greater than that of uninfected cell lysate
(p < 0.05), indicating an overall greater activity of BACE1
in these samples (Fig. 7).

Discussion
By investigating Cpn’s effect on the transcription and
localization of APP-processing secretases, this study
is the first to propose a mechanism by which a respiratory strain of Cpn alters APP processing in an astrocyte
host. Balin et al. [23] identified the Cpn pathogen within
neurons, microglia and astroglia of AD brain tissue. Following this initial study, numerous groups have explored
the roles of astrocytes as hosts for Cpn [45–47]. While
our data indicate that Cpn clearly infects astrocytes, the
percent of astrocytes that were infected decreased over
time. The life cycle of Cpn is complex and involves transitioning from an infectious, elementary body (EB) to a
metabolically active, reticulate body (RB) form of growth
before converting back to an EB that can be released to
infect new cells. Under conditions of stress, Cpn can
persist as viable but noninfectious aberrant bodies (AB),
which can revert back to RBs when conditions favor
active multiplication [48]. It is possible that if cell division occurs more rapidly than Cpn can complete its life
cycle and spread to a new host cell, then the number of
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Fig. 5 Fluorescence intensity of Aβ1-42 is increased in Chlamydia pneumoniae-infected astrocytes. Aβ1-42 (red) and Cpn (green) were visualized by
laser scanning, confocal microscopy (a). To analyze the Z-images using FIJI software, a defined threshold subtraction was applied equally to each
image to determine Aβ1-42 fluorescence intensity (b); mean fluorescence intensity was calculated for infected and uninfected astrocytes at 24, 48
and 72 hpi. Cells (N = 25–30) were analyzed across three biological replicates to reliably conduct a student’s t-test on the fluorescence intensities of
Aβ1-2 in uninfected and Cpn-infected cells. Error bars represent standard error of the mean. Asterisk represents p < 0.05

infected cells relative to uninfected cells will decrease
over time. Alternatively, it is possible that Cpn forms ABs
in astrocytes, which would not subsequently spread to
astrocytes arising from division of uninfected cells. This
also could account for the decrease in % infected astrocytes observed over time.

In this study, we report that having gained access into
the astrocyte host, Cpn promotes significant dysregulation of important AD-related genes directly involved with
APP processing, pathologic lipid trafficking and microtubule dysfunction. While physiologically abnormal and
potentially harmful for a mammalian host, the altered
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Fig. 6 Quantification of sAPPβ/total sAPP in media of uninfected
and Chlamydia pneumoniae infected astrocytes using MSD ELISA.
Conditioned media of uninfected and Cpn-infected cells at each
timepoint post-infection was collected, concentrated, and assayed
in equal volumes for sAPPβ and sAPPα levels. Standard curves of
known concentrations of sAPPβ and sAPPα was used to determine
the concentration of these individual Aβ species. Conditioned media
was obtained from three biological replicates and the assay was
conducted in technical triplicate. Student’s t-test was calculated
using the average sAPPβ/total sAPP ratio of Cpn-infected conditioned
media compared to that of uninfected conditioned media. Asterisk
represents p < 0.05

expression of these genes may have distinct benefits for
Cpn infecting target cells. For example, Cpn infection of
endothelial cells, monocytes, and macrophages has been
shown to alter the expression of lipid homeostasis genes
[40, 42, 49] and allow the acquisition and utilization of
host lipids by Cpn as the pathogen is unable to synthesize
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them de novo [50]. The increased mRNA levels of apolipoprotien E (ApoE) and lipoprotein lipase (LPL) observed
in Cpn-infected astrocytes relative to uninfected cells at
6 hpi may therefore be necessary to allow Cpn to initiate
infection within the astrocyte host. In addition, APOE
has been shown to play a role in the attachment and
internalization of several intracellular pathogens, including Cpn [51–53]. The observed early increase in ApoE
transcript expression may enhance internalization of Cpn
EB’s during infection. Cpn-induced changes in host gene
expression presumably evolved to enhance the infectivity of the bacterium, while potential AD-related pathologic effects associated with altered host gene expression
would be an indirect consequence of Cpn infection.
It is conceivable that the initial increase in transcriptional ApoE expression has a direct impact on expression of APP. A recent study noted that the binding of glial
ApoE to its receptors enhances the transcription of APP
through activating the transcription factor activator protein-1 (AP-1) and its associated family of downstream
effectors [54], the consequence of which may account for
the 30% increase in APP transcription seen at 6 hpi. Furthermore, infection of endothelial cells by Cpn activates
AP-1, and activation of this transcription factor regulates Cpn-induced inflammation [55]. If a similar scenario occurs in Cpn-infected astrocytes, AP-1 may play
a role in mediating Cpn-triggered neuroinflammation as
well as modulating levels of APP, and indirectly, Aβ levels. Data presented here indicate that Cpn stimulated
transcription of the proinflammatory cytokine interleukin 1α (IL1α), suggesting that infection of astrocytes by
Cpn promoted an inflammatory response. Moreover, a

Fig. 7 BACE1 activity is increased and ADAM10 activity is decreased in Chlamydia pneumoniae infected astrocytes. FRET-based assays were used to
quantify the activity of ADAM10 and BACE1 enzyme activity generated by Cpn-infected and uninfected cell lysates at 48 hpi. Fluorescence of the
5-FAM or HiLyte Fluor 488 dyes conjugated to ADAM10 or BACE1-specific substrates was detected as a result of cleavage by the respective enzymes
and compared back to fluorescence intensity of known dye concentrations. The quantified dye concentration from ADAM10 and BACE1 fluorescent
substrate cleavage from (N = 4) biological replicates of Cpn-infected and uninfected cell lysates is presented as an average in the histograms. Error
bars represent standard error of the mean. Asterisk represents p < 0.05
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study by Lim et al. [41] reported that Cpn can activate an
inflammatory response in monocytes, which, if occurring
in microglial cells of the central nervous system, would
reactivate nearby astrocytes. It is likely that Cpn infection in the human brain would trigger an inflammatory
response that would exacerbate neurodegeneration associated with AD.
In this study, it is shown that Cpn infection of astrocytes decreased levels of microtubule-associated protein tau (MAPT) and microtubule-associated protein 2
(MAP2) mRNA, and increased that of glycogen synthase
kinase 3-β (GSK3β), a kinase that can phosphorylate tau.
A decrease in tau protein would destabilize host microtubules, whereas an increase in tau phosphorylation would
subsequently decrease tau binding to, and stabilization
of, microtubules [56]. An increase in GSK3β activity in
Cpn-infected astrocytes could potentially enhance the
formation of neurofibrillary tangles, which are composed
of hyperphosphorylated tau proteins, thereby contributing to tau-mediated pathology that occurs in AD.
Changes in the expression of ADAM10, BACE1, and
PSEN1 in Cpn-infected astrocytes will directly affect
the processing of APP. In the present study, we observed
significant increases in the expression of ADAM10
mRNA by 40–50% in Cpn-infected astrocytes relative
to uninfected cells, as well an increase in the full length
ADAM10 protein. However, it is important to note that
the ADAM10 proenzyme needs posttranslational processing to be active and thus protein levels determined
in this study may not accurately represent enzymatically
active ADAM10 [7, 12]. In fact, ADAM10 protein levels
tended to increase with Cpn infection while enzymatic
activity was diminished at 48 hpi. These data suggest
that posttranslational modification and/or trafficking of
ADAM10 may differ in infected and uninfected astrocytes, resulting in decreased α-secretase-mediated nonamyloidogenic cleavage of APP in Cpn-infected cells.
Protein levels of both BACE1 and PSEN1 in Cpninfected astrocytes progressively increased from 24 to
72 hpi relative to uninfected cells. Relative mRNA levels
were greatest at 48 hpi for BACE1 and 6 hpi for PSEN1,
indicating that the proteins persisted after transcription
of these genes returned to levels consistent with that seen
in uninfected astrocytes. The progressive increase in the
amount of BACE1 and PSEN1 in Cpn-infected astrocytes
over time paralleled the observation that Aβ1-42 labeling
was greatest in infected cells at 48 and 72 hpi. It has been
shown that in the presence of Aβ1-42, BACE1 activity is
elevated because of impaired lysosomal degradation of
BACE1, indicating that increased pro-amyloidogenic
processing of APP favors persistence of this β-secretase
[57, 58]. This positive feedback between Aβ1-42 and
BACE1 levels may have occurred in our Cpn-infected
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astrocytes. Furthermore, it has been shown that lowdensity lipoprotein receptor-related protein 1 (LRP1)
regulates BACE1 expression and activity by directing the
β-secretase to lysosomes for degradation, while a loss of
LRP1 expression correlates with an increase in BACE1
activity [59]. Thus the decreased transcription of LRP1
observed in Cpn-infected astrocytes may contribute to
the increase in BACE1 expression and activity observed
in infected astrocytes.
The lack of a significant increase in the fluorescence
intensity of Aβ1-42 at 24 hpi suggests that prior to 24 hpi,
the pro-amyloidogenic pathway has not been upregulated. If the increase in APP mRNA observed in Cpninfected astrocytes at 6 hpi signals an increase in APP
protein, then the surplus APP within the cell is processed by the non-amyloidogenic pathway at an early
time of infection. However, at 48 to 72 hpi, the significant increase in Aβ1-42 fluorescence labeling in infected
astrocytes suggests that in the presence of Cpn, either
pro-amyloidogenic processing of APP is stimulated and/
or there is decreased clearance of toxic, intracellular
Aβ products. The increased protein concentration of
BACE1 and PSEN1 present in infected astrocytes at 48
and 72 hpi supports the conclusion that increased processing of APP may be responsible for the greater intracellular accumulation of Aβ1-42, however doesn’t rule out
the possibility of decreased clearance of Aβ. Our data
indicating that the ratio of sAPPβ per total sAPP (sAPPα
and sAPPβ) was significantly increased in Cpn-infected
astrocytes at 48 and 72 hpi further supports the conclusion that APP processing favored the pro-amyloidogenic
pathway as the infection progressed. These results could
be explained by either an increase in BACE1-mediated
cleavage and/or a decrease in ADAM10-mediated cleavage of APP. Interestingly, enzyme activity assays for
BACE1 and ADAM10 indicated that at 48 hpi, enzymatic activity in Cpn-infected astrocytes was increased
for BACE1 and decreased for ADAM10 relative to that
measured in uninfected cells.
Our study supports the postulate that the mechanism
by which Cpn induces AD pathology centers on the ability of the pathogen in astrocytes to temporally alter the
expression and activity of the α- and β-secretases, and
thereby alter the balance between the non- and pro-amyloidogenic APP processing pathways that occurs in uninfected cells. This study is the first to quantify the altered
regulation of the predominant α, β-, and γ-secretases in
the CNS, namely ADAM10, BACE1, and PSEN1, respectively, and Aβ1-42 in human astrocytes infected with Cpn.
We have demonstrated that Cpn infection causes a significant increase in the amyloidogenic processing of
APP, which correlates with increased protein levels and
activity of the rate-limiting enzyme, BACE1. Whether

Al‑Atrache et al. BMC Neurosci

(2019) 20:6

through upregulating the transcriptional or post-transcriptional expression of BACE1 and the subunits of
γ-secretase and/or simultaneously disrupting normal
secretase trafficking, severe downstream effects on the
CNS may result secondary to Cpn infection. Over time,
Cpn-induced astrocyte activation culminating in neuroinflammation, altered APP processing favoring the amyloidogenic pathway, dysregulation of tau expression and
function, and eventually neuronal death causes chronic,
irreversible damage, resulting in pathology similar to that
found in the CNS of AD patients.

Future directions
This investigation explores a potential Cpn-induced
mechanism for Aβ formation by focusing on the pathway of APP processing by proamyloidogenic secretases,
thereby identifying a putative early event triggering
AD-associated pathology. While this study is the first
to model a stable, Chlamydia pneumoniae-infection of
human astrocytes in vitro and investigate its downstream
effects on AD-related secretases, numerous additional
studies can be conducted to further support our conclusions. The STTG1 human astrocytoma cell line has been
used as a viable astrocyte model for AD [31–34]. Considering Cpn has been found in multiple areas of human
cortex and vasculature as reported by Balin et al. [23],
reproducing Cpn infection in additional cell types such
as other astrocyte and glial cell lines, neuronal cells, and
endothelial cells may provide a more thorough understanding of in vivo Cpn infection. Reversing the pathologic effects of Cpn infection with anti-microbial or
anti-inflammatory medication may provide a viable therapeutic option for AD. In support of this, Hammond et al.
[60] demonstrated decreased cerebral Aβ load in BALB/c
mice inoculated with Cpn and subsequently treated with
Moxifloxacin. Recent studies implicating pathogens in
AD, including this current study, suggest that eliminating
infectious triggers for AD pathology may be beneficial as
a therapeutic target for preventing the initiation or progression of AD (Additional file 2).
Conclusions
This study examines the effect of Chlamydia pneumoniae
infection on astrocytes, a major cell type in the CNS that
plays an important role in establishing a state of neuroinflammation and neurodegeneration in the brain. Specifically, the data suggest that infection by Chlamydia
pneumoniae promotes the pro-amyloidogenic pathway
of APP processing by manipulating the expression and
activity of the major secretases involved in generating
toxic and nontoxic fragments of APP. Pro-inflammatory
processes in the brain, and environmental stimuli that
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favor the pro-amyloidogenic pathway of APP processing,
are emerging as potential triggers for the pathology associated with AD. We present evidence of an association
between AD pathology and infection with Chlamydia
pneumoniae, supporting the concept of an infectious etiology as a candidate to be considered in the pathogenesis of late onset AD. Furthermore, this study presents a
potential target for preventing or slowing the progression
of this neurodegenerative disease.

Additional files
Additional file 1: AD array tables. Table S1. AD-associated genes whose
expression was significantly altered in Cpn-infected cells relative to
uninfected cells at 6 hpi. Table S2. AD-associated genes whose expression
was significantly altered in Cpn-infected cells relative to uninfected cells at
24 hpi. Table S3. AD-associated genes whose expression was signifi‑
cantly altered in Cpn-infected cells relative to uninfected cells at 48 hpi.
Table S4. AD-associated genes whose expression was significantly altered
in Cpn-infected cells relative to uninfected cells at 72 hpi. Description:
These tables list the Alzheimer-associated genes whose expression in Cpninfected cells significantly differed from that of uninfected cells. The genes
examined were included in the Human Alzheimer Disease R
 T2 Profiler
™
PCR Array (Qiagen, PAHS-057ZC) that profiled 84 different Alzheimerassociated genes.
Additional file 2: MSD ELISA %CV values. Table S1. Percent CV for
soluble APPα. Table S2. Percent CV for soluble APPβ. Description: These
tables list intra- and inter-ELISA % coefficient of variation (CV) for the data
generated by MSD ELISA.
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